SCHEDULE: Squadron Master Fund Reports 9.8% Stake in InMed Pharmaceuticals

Squadron Master Fund LP, along with its affiliates, has disclosed beneficial ownership of 325,000 shares, representing 9.8% of InMed Pharmaceuticals Inc.'s common stock.

Summary

• Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn, and William Blank have collectively reported beneficial ownership of 325,000 shares of InMed Pharmaceuticals Inc. common stock.
• This holding represents 9.8% of the company's outstanding common shares, based on 3,314,063 shares as of May 4, 2026.
• Squadron Capital Management, LLC acts as the investment adviser to Squadron Master Fund LP and other private funds.
• Matthew Sesterhenn and William Blank, as Partners of Squadron Capital Management, LLC, may be deemed beneficial owners due to their investment and voting discretion.
• All reporting persons expressly disclaim beneficial ownership beyond their direct roles, stating the filing should not be construed as an admission of beneficial ownership of the reported securities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While a significant stake is reported, the explicit disclaimer of beneficial ownership by the reporting entities tempers any strong positive or negative sentiment.

Positives

• Significant stake of 9.8% held by Squadron Master Fund LP indicates substantial investor confidence or strategic interest.
• The reporting entities are established investment managers, suggesting a professional and strategic approach to their holdings.

Negatives

• The reporting entities expressly disclaim beneficial ownership, which could indicate a lack of direct control or a specific investment strategy that avoids direct ownership claims.
• The filing does not provide context for the acquisition of these shares or future intentions, leaving the market to speculate on the purpose of the stake.

Risks

• Potential for future share sales by Squadron Master Fund LP could create downward pressure on InMed Pharmaceuticals' stock price.
• The disclaimer of beneficial ownership might suggest a complex ownership structure or a strategy that could lead to future uncertainty for investors.
• The filing does not detail the specific investment strategy or rationale behind acquiring this stake, leaving room for interpretation and potential market volatility.

Future Outlook

The filing does not contain any forward-looking statements or guidance from InMed Pharmaceuticals Inc. It solely reports on the beneficial ownership of securities by Squadron Master Fund LP and related entities.

Management Comments

• Squadron Master Fund LP, Squadron Capital Management, LLC, Matthew Sesterhenn and William Blank expressly disclaim beneficial ownership over any of the securities reported in this statement, and the filing of this statement shall not be construed as an admission that Squadron Capital Management, LLC or Mr. Sesterhenn and Mr. Blank are the beneficial owner of any of the securities reported herein.

Industry Context

StockSavvy.ai notes that Schedule 13G filings typically indicate passive investment stakes, often by institutional investors. The 9.8% holding by Squadron Master Fund LP suggests a significant, though potentially non-controlling, interest in InMed Pharmaceuticals, a company operating in the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders: The filing may influence investor perception of InMed Pharmaceuticals due to the significant stake held by Squadron Master Fund LP, although the disclaimer of beneficial ownership adds a layer of complexity.
• Management: The company's management will be aware of this substantial shareholder, which could influence strategic discussions and future corporate actions.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Monitor future filings from Squadron Master Fund LP and related entities for any changes in their stake or investment strategy.
• Observe InMed Pharmaceuticals Inc.'s subsequent corporate actions and disclosures for potential impacts of this significant shareholder.

Key Dates

Recommendation

This Schedule 13G filing indicates a significant passive stake by Squadron Master Fund LP, but the explicit disclaimer of beneficial ownership suggests a lack of intent to control or influence the company. Without further information on the fund's strategy or InMed Pharmaceuticals' performance, a 'hold' recommendation is prudent, awaiting more clarity on the implications of this ownership.

Keywords

InMed Pharmaceuticals, Schedule 13G, Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn, William Blank, Beneficial Ownership, Common Shares, SEC Filing, Investment Adviser